Article: Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review.
Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2022 Volume 36, Issue 3, Page(s) 260–269
Abstract: Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant ...
Abstract | Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical trials have been published regarding the anti-VEGF use in ROP, along with multiple other studies looking into the different agents, doses, techniques, and possible complications. Anti-VEGF therapies can be considered as a safe and effective option for managing ROP. More longitudinal randomized clinical trials are necessary to evaluate the preferred treatment agent, the appropriate dose, best follow-up protocol, and the long-term ocular and systemic outcomes following treatment. |
---|---|
Language | English |
Publishing date | 2022-10-14 |
Publishing country | India |
Document type | Journal Article |
ZDB-ID | 2515644-5 |
ISSN | 1319-4534 |
ISSN | 1319-4534 |
DOI | 10.4103/sjopt.sjopt_12_22 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.